Some of the most well-known candidates, including aducanumab, lecanemab and donanemab, have shown limited success in reducing ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

In phase II and III trials of nearly 2,000 participants, the frequency of ARIA was 37% in the donanemab group compared with 14.2% in the placebo group, reported John Sims, MD, of Eli Lilly and Company ...

Now, new research from the company that produces donanemab has confirmed the findings of early studies that suggested the drug's deadly risks. Scientists at pharmaceutical firm Eli Lilly found the ...

In phase II and III trials of nearly 2,000 participants, the frequency of ARIA was 37% in the donanemab group compared with 14.2% in the placebo group, reported John Sims, MD, of Eli Lilly and ...

Eli Lilly's senior medical director and associate vice president, respectively. 'Therefore, safety monitoring is necessary with donanemab.' The medication, which patients receive through a ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...